Form 8-K BIOGEN INC. For: Apr 24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Form 8-K BIOGEN INC. For: Apr 24
April 25, 2024 6:39 AM EDT
RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $317.00 (from $326.00) while maintaining a Outperform rating.
The analyst comments "Some encouraging signs for the launch products Skyclarys, Leqembi, and Zurzuvae; while the base business remains pressured and a more... More
April 24, 2024 9:06 AM EDT
JPMorgan analyst Chris Schott reiterated a Neutral rating on Biogen (NASDAQ: BIIB).
The analyst comments "This morning, BIIB reported 1Q results that were in line on the top line (Spinraza miss/Tecfidera beat) and ahead on the bottom line and the company... More
April 24, 2024 7:57 AM EDT
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $260.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "Topline miss countered by operating expense efficiency gains from "Fit for Growth" initiative. Topline miss (-1% vs. cons.) mostly driven by Spinraza... More
